anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Ofloxacin
Trial phase: Phase 3
ATC code: A02BD10 | J01MA01 | J01MA12 | J01RA05 | J01RA09 | S01AE01 | S01AE05 | S02AA16
SMILES: CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 450
Group description: Levofloxacin (750 mg) was administered IV q24h. At minimum, the first 3 doses were administered IV. After an IV-to-PO transition, provided adequate clinical improvement, participants were administered 750 mg PO QD for a total therapy of 7 dosing cycles.
Eligibility criteria:
Inclusion Criteria:

1. Male and female participants with either:

a. Pyelonephritis and normal urinary tract anatomy (approximately 50% of the total population), OR b. cUTI with at least 1 of the following conditions associated with a risk for developing cUTI: i. Indwelling urinary catheter ii. Urinary retention (approximately 100 milliliters of residual urine after voiding) iii. Neurogenic bladder iv. Partial obstructive uropathy (such as, nephrolithiasis, bladder stones, and ureteral strictures) v. Azotemia of renal origin (not congestive heart failure or volume related) such that the serum blood urea nitrogen (BUN) is elevated (>20 mg/deciliters) AND the serum BUN: creatinine ratio is <15 vi. Surgically modified or abnormal urinary tract anatomy (such as, bladder diverticula, redundant urine collection system) EXCEPT surgery within the last month

Exclusion Criteria:

1. Concurrent use of non-study antibacterial drug therapy that would have a potential effect on outcome evaluations in participants with cUTI, including:

Participants with a history of a levofloxacin-resistant urinary tract infection
Likely to receive ongoing antibacterial drug prophylaxis prior to the late Post-Treatment visit (such as, participants with vesiculo-ureteral reflux)
Intervention: Icariin
Trial phase: Phase 3
SMILES: COc1ccc(-c2oc3c(CC=C(C)C)c(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)cc(O)c3c(=O)c2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Icariin will be given 100 mg/day. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 for participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.

Icariin: Participants will receive 20% icariin (100 mg/day) in a commercially available over-the-counter Horny Goat Weed supplement. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.
Eligibility criteria:
Inclusion Criteria:

Current BPD I, II or NOS and cocaine or alcohol use disorder with HAMD score of ≥ 15
Cocaine or alcohol use with 5 days of initiating study drug
Men and women
Age 18-70 years

Exclusion Criteria:

Psychotic features
Non-English speakers
Treatment resistant depression defined as failure of a trial of antidepressants (≥ 4 weeks at a therapeutic dose) in current episode
Major medical condition including heart, lung, liver or renal disease, cancer, neurological or immunological conditions
Vulnerable populations including prisoners, cognitively impaired individuals, and pregnant or nursing women
Prior side effects or allergic reactions to icariin-containing preparations
Change in psychotropic medications within 14 days of study entry
Current suicidal ideation (plan and intent), a suicide attempt within the past 12 months or history of > 1 lifetime suicide attempt
Intervention: Simvastatin
Trial phase: Phase 1
ATC code: A10BH51 | C10AA01 | C10BA02 | C10BA04 | C10BX01 | C10BX04
SMILES: CCC(C)(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 29
Group description: Administered as a single oral 20 mg dose on Day 1.
Eligibility criteria:
Inclusion Criteria:

Normal healthy male and female volunteers
Serum ferritin, hemoglobin and erythrocyte indices within normal range

Exclusion Criteria:

Evidence of any active or chronic disease
Intervention: Erbitux
Trial phase: Phase 2
SMILES: C=C1N(CCCCCC(=O)O)c2ccccc2C1(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 24
Group description: Cetuximab 400 mg/m2 IV over 120 minutes loading dose > 4 days prior to initiation of radiation; Cetuximab 250 mg/m2 IV over 60 minutes weekly weeks 2-7 concurrent with Radiation therapy 60-66 Gy in 2 Gy daily fractions

Cetuximab: 400 mg/m2 IV over 120 minutes week 1; 250 mg/m2 IV over 60 minutes weekly weeks 2-7

Radiation Therapy: Radiation Therapy 60-66 Gy in 2 Gy fractions starting week 2 of Cetuximab
Eligibility criteria:
Inclusion Criteria:

Pathologically (histologically) proven diagnosis of cutaneous squamous cell carcinoma of the head and neck
Clinical stage >/= T3 or >/= N1, M0 including no distant metastases
Gross total resection of the primary tumor with curative intent must be completed within 7 weeks of registration
Performance status of 0-1 within 2 weeks prior to registration
Age >/= 18
Adequate labs within 2 weeks prior to registration

Exclusion Criteria:

Prior invasive malignancy unless disease free for a minimum of 3 years; noninvasive cancers (For example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) are permitted even if diagnosed and treated < 3 years ago. Patients with a history of T1-2, N0, M0 resected differentiated thyroid carcinoma are considered eligible.
Prior systemic chemotherapy or anti-epidermal growth factor therapy for the study cancer or for a different prior cancer
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Intervention: Tranexamic acid
Trial phase: Not Applicable
ATC code: B02AA02
SMILES: NC[C@H]1CC[C@H](C(=O)O)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 39
Group description: 1000mg tranexamic acid; given over 15 minutes into the vein once prior to surgery.

Tranexamic Acid
Eligibility criteria:
Inclusion Criteria

Subjects undergoing major oncologic surgery for standard of care purposes (to include, but not limited to: liver resections, radical cholecystectomy, pancreaticoduodenectomy (Whipple procedure), esophagectomy, gastrectomy, colectomy, debulking with hyperthermic intraperitoneal chemotherapy, prostatectomies, nephrectomies and partial nephrectomies)
Male or female > 18 years of age
Subject agrees to participate in this study and provides informed consent

Exclusion Criteria

Subjects with a history of hypercoagulopathy, deep vein thrombosis or pulmonary embolism
Subjects that are on therapeutic anticoagulation or therapeutic antiplatelet medications at the time of surgery other than Aspirin
Subjects with a history of TIA or stroke
Subjects with a history of atrial fibrillation
Subjects with a known thrombus
Baseline creatinine level greater than 2.83 mg/dL
Subjects with known hypersensitivity to tranexamic acid
Adults unable to provide informed consent
Children
Pregnant women
Prisoners
Non-English speaking subjects
Any other medical condition including mental illness or substance abuse deemed by the investigator to be likely to interfere with a subject's ability to provide informed consent, cooperate and take part in this research study
Intervention: Acipimox
Trial phase: Phase 2 | Phase 3
ATC code: C10AD06
SMILES: Cc1cnc(C(=O)O)c[n+]1[O-]
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 8
Group description: 250 mg at 0 and 180 minutes (one day)

acipimox
Eligibility criteria:
Inclusion Criteria:

Type 2 Diabetes
HbA1C >6%

Exclusion Criteria:

Insulin therapy (except: BOT=basal supported oral therapy)
Known heart disease including coronary artery disease, cardiomyopathy, history of cardiac surgery
Known intolerance against niacins
Known contra-indications against magnetic resonance (MR-) examinations
Intervention: Aminocaproic acid
Trial phase: Phase 4
ATC code: B02AA01
SMILES: NCCCCCC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 40
Group description: One arm: Epsilonaminocaproic acid 10 gr IV, followed by 1 gr/hr infusion Second arm: placebo

Epsilonaminocaproic acid: One group receives Epsilonaminocaproic acid, 10 gr IV bolus, followed by 1 gr/hr. Second group receives placebo.

No adverse advents to report.
Eligibility criteria:
Inclusion Criteria:

All adult patients, undergoing first time sternotomy for Coronary artery bypass grafting/Aortic valve replacement/aortic surgery

Exclusion Criteria:

Resternotomy, renal insufficiency, deep hypothermia, age < 18 yrs
Intervention: Solifenacin
Trial phase: Phase 3
ATC code: G04BD08 | G04CA53
SMILES: O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 23
Group description: Children aged 6 months to < 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods.
Eligibility criteria:
Inclusion Criteria:

Myelomeningocoele
Documented diagnosis of NDO, confirmed by urodynamics
DSD (detrusor sphincter dyssynergia)
Practicing clean intermittent catheterization (CIC)

Exclusion Criteria:

Know genitourinary condition (other than NDO) that may cause incontinence
Bladder augmentation surgery
Current faecal impaction
Electro-stimulation therapy within 2 weeks prior to visit
Subjects with the following gastro-intestinal problems: partial or complete obstructions, decreased motility like paralytic ileus, subjects at risk of gastric retention
Reflux grade 3 to 5
Current urinary tract infection
Intervention: Technetium Tc-99m pentetic acid
Trial phase: Not Applicable
SMILES: O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CCN(CC(=O)[O-])CC(=O)[O-].[H+].[H+].[Tc]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: Patients undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT at baseline, mid-radiation therapy (up to 1 week post-treatment), and at 3-6 months post-treatment. Patients also undergo a pre-treatment 18F FDG PET/CT scan per standard of care.

Computed Tomography: Undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT

Computed Tomography: Undergo 18F FDG PET/CT

Fludeoxyglucose F-18: Undergo 18F FDG PET/CT

Positron Emission Tomography: Undergo 18F FDG PET/CT

Single Photon Emission Computed Tomography: Undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT

Technetium Tc-99m Albumin Aggregated: Undergo 99mTc-MAA SPECT/CT

Technetium Tc-99m DTPA: Undergo 99mTc-DTPA SPECT/CT
Eligibility criteria:
Inclusion Criteria:

Cancer patients receiving radiation treatment to the thorax to at least 45 Gy; patient must have pathologic confirmation of diagnosis, or have an enlarging lung mass on at least two scans spaced 3 months apart, and FDG avidity on PET scan
Patients must be planned for at least 45 Gy of thoracic radiation
Patients are not required to have measurable disease; post-operative patients (patients who have had surgical resection of the lung) are eligible

Patients must have pulmonary function as defined below:

Abnormal pulmonary function test within 3 months of study entry
Prior radiation to the lungs
Prior surgical resection of lung tissue (i.e. wedge resection, lobectomy, or pneumonectomy)
Clinical diagnosis of chronic obstructive pulmonary disease (COPD) or emphysema
Ongoing oxygen use
There are no limits on prior therapy; patients are allowed to have prior chemotherapy, radiation therapy, and surgery; patients are allowed to have concurrent chemotherapy with radiation treatment; patients are allowed to have chemotherapy after radiation treatment; patients are not allowed to have planned lung resection after radiation
Ability to understand and the willingness to sign a written informed consent document
Patients will typically be enrolled on this trial prior to beginning the radiation treatment course; however, if a patient has had a SPECT/CT 99mTc-MAA and 99mTc-DTPA scan as part of routine medical care within 6 weeks prior to initiation of radiation treatment, he/she is eligible for trial enrollment up to the last day of the radiation treatment course

Exclusion Criteria:

Patients must not be planned for lung resection after radiation therapy
Patients receiving < 45 Gy radiation
Patients who received radiation to the chest within the past 6 months
Patients unable to tolerate a SPECT/CT 99mTc-MAA and 99mTc-DTPA scan
Patients who are not planning to adhere to the required follow up schedule as outlined in this protocol
Pregnant women
Women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception
Patients unable to provide informed consent
Intervention: Plecanatide
Trial phase: Phase 3
ATC code: A06AX07
SMILES: CC(C)CC(NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(N)CC(N)=O)CSSCC(NC(=O)C(C)NC(=O)C(C(C)C)NC(=O)C(CC(N)=O)NC(=O)C(C(C)C)NC2=O)C(=O)NC(C(C)O)C(=O)NCC(=O)N1)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 474
Group description: Plecanatide tablets 3.0 mg QD for 12 weeks
Eligibility criteria:
Inclusion Criteria:

Male or female aged 18-80, inclusive
Meets modified Rome III criteria for functional chronic idiopathic constipation for at least 3 months with symptom onset for at least 6 months
Completed a colonoscopy in accordance with AGA colon cancer screening guidelines (5 years), with no clinically significant findings
Willing to maintain a stable diet during the study

Exclusion Criteria:

Loose stool (mushy) or watery (Bristol score 6 or 7) stool in the absence of any laxative or prohibited medicine for > 25% of BMs during the 3 months prior to screening visit OR during the 14 day pre-treatment assessment
Active peptic ulcer disease, diabetes or hypertension not adequately treated or not stable
History of cathartic colon, laxative, enema abuse, or ischemic colitis
Fecal impaction within 3 months of screening
Patient has had /has any: diseases or conditions associated with constipation (GI or CNS), structural abnormality of the GI tract or gastric bypass surgery, pelvic floor dysfunction, pseudo-obstruction, active infectious gastritis, diverticulitis, anal fissures or any disease or condition that can affect GI motility or defecation or can be associated with abdominal pain
Unexplained and clinically significant "alarm symptoms" including lower GI bleeding, iron-deficiency anemia, weight loss or systemic signs of infection or colitis
Major surgery, stroke or MI within 60 days of screening
Participated in a previous plecanatide clinical trial
Intervention: Diclofenac
Trial phase: Phase 4
ATC code: D11AX18 | M01AB05 | M01AB55 | M02AA15 | S01BC03 | S01CC01
SMILES: O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 25
Group description: Administration of Zipsor® (liquid filled capsules) to patients with mild to moderate acute pain: 25 mg/every 6 hours/up to 4 days treatment. Drug taken by mouth.
Eligibility criteria:
Inclusion Criteria:

Male and female subjects between 12-17 years of age.
Subjects must be post-op, having mild or moderate acute pain.

Other inclusions apply.

Exclusion Criteria:

Subject has a known history of allergic reaction, hypersensitivity to diclofenac, aspirin, acetaminophen, or reaction to the non-active ingredients of the study medication.
Subject has been taking analgesic for 48-72 hours prior to Screening.
Subject has a history of any GI event greater than 6 months before Screening.
Subject is currently receiving any medication that is contraindicated for use concomitantly with diclofenac or acetaminophen.
Subject has previously participated in another clinical study of Zipsor or taking Zipsor for any other indication.
Subject is requiring treatment for pre-existing hypertension.

Other exclusions apply.
Intervention: Losartan
Trial phase: Not Applicable
ATC code: C09CA01 | C09DA01 | C09DB06
SMILES: CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
Sex: Male
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Losartan
Eligibility criteria:
Inclusion Criteria:

Duchenne muscular dystrophy patients of all ages
Null mutation of the dystrophin gene or muscle with <5% dystrophin
Doppler echocardiogram with ejection fraction (EF) <55% within 30 days of enrollment
Ability to cooperate for testing
Glucocorticoid treatment acceptable including daily or weekend administration of prednisone or deflazacort

Exclusion Criteria:

Patients with EF 55% or greater
Patients with EF <40% after washout
Patients taking >5 mg lisinopril, or >25 mg losartan or >5 mg enalapril
Skeletal deformities or pulmonary anatomical variants that preclude consistent measures of Doppler echocardiography
Intervention: Desmopressin
Trial phase: Phase 2
ATC code: H01BA02
SMILES: N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 14
Group description: Arm receiving DDAVP prior to the operation. Drug is administered intravenously at .3mcg per kg, over 30 minutes prior to the operation.

DDAVP: Patients Receiving DDAVP prior to operation
Eligibility criteria:
Inclusion Criteria:

Undergoing Rhinoplasty where nasal bone osteotomy is necessary

Exclusion Criteria:

Heart Disease
Renal Disease with decreased GFR
Liver Disease
Intervention: Lidocaine
Trial phase: Phase 3
ATC code: C01BB01 | C05AD01 | D04AB01 | N01BB02 | N01BB52 | R02AD02 | S01HA07 | S02DA01
SMILES: CCN(CC)CC(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 11
Group description: Lidocaine infused at 0.5 mg/kg/hour.

Lidocaine
Eligibility criteria:
Inclusion Criteria:

Male and Female >/= 18 years of age Patients undergoing first-time fusion surgery or surgery to revise a prior fusion Able to read, write and speak in English, and able to give informed consent for the study

Exclusion Criteria:

Any disease associated with major organ dysfunction renal dysfunction hepatic dysfunction cardiac dysfunction
Intervention: Omeprazole
Trial phase: Phase 2
ATC code: A02BC01 | A02BC05 | A02BD01 | A02BD05 | A02BD06 | A02BD16 | M01AE52
SMILES: COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: Esomeprazole 40mg twice daily

Esomeprazole
Eligibility criteria:
Inclusion Criteria:

Cystic fibrosis
Age > 18 years
Stable maintenance medical regimen during the previous 6 weeks.
Negative pregnancy test (women of childbearing potential) at both screening and baseline visits.
Women of childbearing potential must be using medically acceptable contraception.
At least two respiratory exacerbations per year requiring oral and/or intravenous antibiotics for each of the two years prior to study entry, but no more than 4 exacerbations requiring intravenous antibiotics during either of those years.

Exclusion Criteria:

Previous anti-reflux or peptic ulcer surgery,
Use of proton pump inhibitor (PPI) within the past two weeks
Pulmonary exacerbation requiring antibiotics within the previous 2 weeks
Parenteral hyperalimentation
Cigarette smoking
Treatment with azoles, iron, anti-coagulants, digitalis
Use of any investigative drugs within the previous month.
Use of over the counter acid suppressor agents (not including acid neutralizers)
Intervention: Colchicine
Trial phase: Phase 3
ATC code: M04AC01
SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 49
Group description: On the day of surgery, the intervention group will receive 2 doses of colchicine 0.6 mg orally. The first dose will be administered within 4 hours before surgery. The second dose will be given between 6:00PM and 11:59PM after surgery. All patients will receive colchicine 0.6 mg or placebo twice daily orally for 10 days.

Colchicine
Eligibility criteria:
Inclusion Criteria:

All patients ≥55 years of age undergoing intra-thoracic surgery for a resection of tumor in lung.

Exclusion Criteria:

In AF prior to surgery*,
Undergoing minor thoracic interventions/ procedures (i.e., chest tube insertion, needle pleural/lung biopsies, or minor chest-wall surgeries), or

With contraindications to colchicine (i.e., allergy, or myelodysplastic disorders or estimated glomerular filtration rate [e-GFR] <30 mL/min/1.73m)

Clarification: Patients with history of AF who are in sinus rhythm during enrollment will be eligible for recruitment. Patients who have no history of AF and are found to be in AF at the time of enrollment will not be eligible.
Intervention: Lifitegrast
Trial phase: Phase 4
ATC code: S01XA25
SMILES: CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3c(c2Cl)CCN(C(=O)c2ccc4ccoc4c2)C3)C(=O)O)c1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 97
Group description: AR11, administered orally, BID for one week
Eligibility criteria:
Inclusion Criteria:

Male or female between 6 and 12 years of age, inclusive, at the time of Screening.
Diagnosed as meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for ADHD.
A clinician-administered Clinical Global Impression of Severity (CGI-S) score of 3 or greater.
An ADHD Rating Scale (ADHD-RS) score at Screening and Baseline greater than or equal to the 90th percentile normative values for gender and age in at least one of the following categories: hyperactive-impulsive subscale, inattentive subscale, or total score.

Exclusion Criteria:

Secondary or co-morbid diagnoses other than ADHD, with the exception of simple phobias, oppositional defiant disorder, elimination disorders, motor skills disorders, communication disorders, learning disorders, adjustment disorders, and sleep disorders if, in the opinion of the investigator, the associated symptoms do not confound assessment of safety or efficacy.
Clinically significant cognitive impairment as assessed in the clinical judgment of the Investigator.
History of any of the following medical disorders: seizure disorder (excluding a history of febrile seizures), structural cardiac disorders, serious cardiac conditions, hypertension, untreated thyroid disease, glaucoma, Tourette's disorder, or chronic tics.
Clinically significant abnormal ECG finding or abnormal cardiac finding on physical exam (including presence of a pathologic murmur) at Screening.
Use of any psychotropic medication (sedative hypnotics prescribed as a sleep aid at a stable dose for at least 30 days prior to Baseline, at bedtime only, are allowed during the study).
A history of hypersensitivity or intolerance to any formulation of amphetamine or lisdexamfetamine.